全髋关节置换术后阿司匹林预防静脉血栓栓塞非劣效于抗凝药:密歇根州注册研究
基于密歇根关节置换注册协作质量倡议数据库的回顾性队列非劣效性分析,纳入2013年4月1日至2018年12月31日行初次全髋关节置换的59,747例患者,比较单用阿司匹林与单用抗凝药预防静脉血栓栓塞和出血事件。结果显示阿司匹林在复合静脉血栓栓塞事件(OR 0.99,95%CI 0.79-1.26,P < .001)和出血事件(OR 0.62,95%CI 0.52-0.74,P < .001)上均非劣效于抗凝药。结论认为在合适患者中可考虑单用阿司匹林作为全髋关节置换术后静脉血栓栓塞的药物预防。
要点
- 单用阿司匹林在全髋置换术后静脉血栓栓塞预防中非劣效于单用抗凝药。
- 阿司匹林组出血事件风险亦非劣效,且点估计值更低。
- 合适患者可考虑单用阿司匹林作为术后静脉血栓栓塞预防。
核心结论
- 阿司匹林在预防全髋关节置换术后静脉血栓栓塞和出血事件方面非劣效于其他抗凝药。
- 在合适患者中应考虑单用阿司匹林作为全髋关节置换术后静脉血栓栓塞的药物预防。
研究设计与样本
- 回顾性队列的非劣效性分析,数据来自密歇根关节置换注册协作质量倡议数据库。
- 纳入2013年4月1日至2018年12月31日行全髋关节置换的患者,由密歇根州61家医院的355名外科医生实施。
- 手术机构涵盖小型社区医院至大型学术和非学术中心。
主要发现
- 共纳入59,747例患者,其中女性32,878例(55.03%),平均年龄64.5岁。
- 复合静脉血栓栓塞事件共462例(0.77%),单用阿司匹林组221例(0.71%),单用抗凝药组129例(0.80%)。
- 阿司匹林对复合静脉血栓栓塞事件非劣效于抗凝药(OR 0.99,95%CI 0.79-1.26,P < .001)。
- 出血事件共767例(1.28%),单用阿司匹林组304例(0.97%),单用抗凝药组281例(1.74%)。
- 阿司匹林对出血事件非劣效于抗凝药(OR 0.62,95%CI 0.52-0.74,P < .001)。
关键数值与推荐
- 非劣效性判定基于复合静脉血栓栓塞事件(深静脉血栓或肺栓塞或死亡)和出血事件两个主要结局。
- 单用阿司匹林组复合静脉血栓栓塞事件OR 0.99(95%CI 0.79-1.26,P < .001)。
- 单用阿司匹林组出血事件OR 0.62(95%CI 0.52-0.74,P < .001)。
临床怎么用
- 对于全髋关节置换术后合适患者,可考虑单用阿司匹林作为静脉血栓栓塞的药物预防。
- 选择预防方案时应综合评估静脉血栓栓塞和出血风险。
局限性
- 本研究为回顾性队列设计。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uncertainty remains surrounding the use of aspirin as a sole chemoprophylactic agent to reduce the risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism) and bleeding after primary total hip arthroplasty. METHODS: We performed a non-inferiority analysis of a retrospective cohort of patients undergoing total hip arthroplasty from April 1, 2013 to December 31, 2018. Cases were retrieved from the Michigan Arthroplasty Registry Collaborative Quality Initiative database and performed by 355 surgeons at 61 hospitals throughout Michigan. Surgical setting ranged from small community hospitals to large academic and non-academic centers. The primary outcomes were post-operative venous thromboembolism event or death and bleeding event. RESULTS: Of the 59,747 patients included, 32,878 (55.03%) were female, and the mean age was 64.5. A total of 462 (0.77%) composite venous thromboembolism events occurred. There were 221 (0.71%) and 129 (0.80%) venous thromboembolism events in patients receiving aspirin only and anticoagulants only, respectively. Aspirin was non-inferior to anticoagulants for composite venous thromboembolism events (odds ratio 0.99, 95% confidence interval 0.79-1.26, P < .001). Bleeding events occurred in 767 (1.28%) patients, with 304 (0.97%) and 281 (1.74%) bleeding events in patients receiving aspirin only and anticoagulants only, respectively. Aspirin was non-inferior to anticoagulants for bleeding events (odds ratio 0.62, 95% confidence interval 0.52-0.74, P < .001). CONCLUSION: Aspirin is not inferior to other anticoagulants as pharmacologic venous thromboembolism prophylaxis with regards to post-operative risk of venous thromboembolism or bleeding. Sole use of aspirin for venous thromboembolism prophylaxis after total hip arthroplasty should be considered in the appropriate patient.
引用
- Muscatelli SR, Zheng H, Hughes RE, et al. Non-Inferiority of Aspirin for Venous Thromboembolism Prophylaxis After Hip Arthroplasty in a Statewide Registry. J Arthroplasty. 2021. PMID: 33589277. doi:10.1016/j.arth.2021.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。